Library

Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool.

1 December 2022. doid: 10.1177/02698811221124792

Kwee CM, van Gerven JM, Bongaerts FL, Cath DC, Jacobs G, Baas JM, Groenink L

View publication

Preclinical research suggests that cannabidiol (CBD) may have therapeutic potential in pathological anxiety. Dosing guidelines to inform future human studies are however lacking.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact